Canadian researchers have discovered an approach to interpret blood test results in patients examined for pulmonary embolism (PE), a condition of blood-clotting in the lungs.

The approach applies to D-dimer blood tests used to rule out the presence of blood clot.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The study, led by Hamilton Health Sciences, found that a higher D-dimer level than average could be considered a negative result if the doctor has evaluated the patient to have a low probability of pulmonary embolism.

The approach could reduce the need for CT scans, enabling patients’ to pass quickly through the emergency department.

McMaster University professor of medicine and Hamilton Health Sciences thrombosis specialist Clive Kearon said: “The primary goal of diagnostic testing for pulmonary embolism is to identify which patients should be treated with anticoagulant agents and which should not.

“When a physician is concerned that pulmonary embolism may be present, chest imaging with CT pulmonary angiography is usually done in half of these patients. We wanted to find a way to reduce the number of CT scans that need to be done.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The study evaluated 2,017 patients; 7% had PE on initial diagnostic testing. The average age of those enrolled was 52 years, with female patients forming 66% of the total number of patients studied.

An emergency department physician identified 1, 325 patients as having a low or moderate probability of having a PE. These patients had negative D-dimer results, with none indicating venous thromboembolism during follow-up.

Canadian Institutes of Health Research provided funds for the study, endorsed by the Canadian Venous Thromboembolism Clinical Trials and Outcomes Research.

The Ontario Clinical Oncology Group of McMaster and Hamilton Health Sciences coordinated the study.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact